The diseases we tackle are serious, and every patient has a unique journey. We aim to enable patients to live their best life, whatever that is for them.
We focus on addressing the needs of specific patient populations suffering from severe diseases in our focus areas of neurology and immunology through five core products (in neurology with Vimpat®, Keppra®, Briviact® and Neupro®, and in immunology with Cimzia®). Our promising pipeline has the potential to bring new treatments to patients with severe diseases in these therapeutic areas.
UCB achieved revenues of € 4.9 billion, and net sales of € 4 680 million (€ 4 784 million excluding € −104 million hedging) across our core products and established brands in 2019.